Daiichi Sankyo Announces New Oxycodone Extended Release Tablets "Daiichi Sankyo" for Sustained Cancer Pain Treatment

On March 8, 2017 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) reported that it has launched new generic oxycodone extended release formulations to treat sustained cancer pain: Oxycodone Extended Release 5 mg, 10 mg, 20 mg and 40 mg "Daiichi Sankyo" (date of approval: August 15, 2016; date of listing in the NHI reimbursement price list in Japan: December 9, 2016) (Press release, Daiichi Sankyo, MAR 7, 2017, View Source [SID1234518076]).

This oxycodone extended release tablet is an opioid analgesic providing the degree of analgesia prescribed for various cancers with moderate to severe pain, and the first tablet generic for an oxycodone extended release formulation. Our domestic subsidiary, Daiichi Sankyo Propharma Co., Ltd. (manufacturing and marketing) manufactures from drug substance to formulation using our GWATab technology*.

Daiichi Sankyo expects this drug to be able to contribute to all patients and medical staff by offering a new therapeutic option.

Product summary
Product name
Therapeutic Category
Original brand name
Oxycodone Extended Release tablets 5mg "Daiichi Sankyo"
Oxycodone Extended Release tablets 10mg "Daiichi Sankyo"
Oxycodone Extended Release tablets 20mg "Daiichi Sankyo"
Oxycodone Extended Release tablets 40mg "Daiichi Sankyo"
Sustained cancer pain treatment
OxyContinⓇTablets 5mg
OxyContinⓇTablets 10mg
OxyContinⓇTablets 20mg
OxyContinⓇTablets 40mg

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

*GWATab (Gelling WAter soluble polymer matrix Tablet) technology is proprietary technology that combines a drug substance with a water-soluble polymer, releasing medication along a wide range of the gastrointestinal tract after dosing, for sustained drug efficacy.